Indivior/$INDV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Indivior
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Ticker
$INDV
Sector
Primary listing
Employees
1,000
Headquarters
Website
Indivior Metrics
BasicAdvanced
$3.1B
59.40
$0.42
0.96
-
Price and volume
Market cap
$3.1B
Beta
0.96
52-week high
$25.00
52-week low
$7.33
Average daily volume
3.6M
Financial strength
Current ratio
0.901
Quick ratio
0.713
Long term debt to equity
-131.128
Total debt to equity
-142.412
Interest coverage (TTM)
6.78%
Profitability
EBITDA (TTM)
336
Gross margin (TTM)
83.97%
Net profit margin (TTM)
4.52%
Operating margin (TTM)
23.10%
Effective tax rate (TTM)
57.94%
Revenue per employee (TTM)
$1,170,000
Management effectiveness
Return on assets (TTM)
13.14%
Return on equity (TTM)
-28.04%
Valuation
Price to earnings (TTM)
59.403
Price to revenue (TTM)
2.684
Price to book
-12.03
Price to tangible book (TTM)
-11.71
Price to free cash flow (TTM)
20.057
Free cash flow yield (TTM)
4.99%
Free cash flow per share (TTM)
1.233
Growth
Revenue change (TTM)
2.27%
Earnings per share change (TTM)
-147.83%
3-year revenue growth (CAGR)
11.86%
10-year revenue growth (CAGR)
1.04%
3-year earnings per share growth (CAGR)
-26.62%
10-year earnings per share growth (CAGR)
-15.33%
What the Analysts think about Indivior
Analyst ratings (Buy, Hold, Sell) for Indivior stock.
Bulls say / Bears say
Indivior has faced significant legal issues along with rising competitive pressure, causing its share price to drop around 40% in recent months (FT)
After a strategic review, Indivior has stopped promoting and marketing its schizophrenia drug PERSERIS, and expects SUBLOCADE sales to remain flat while SUBOXONE revenues decline, indicating weak performance in key products (The Guardian)
Management is now focused on narrowing product lines and R&D activities in response to revenue challenges and legal settlements, which could limit future pipeline innovation (FT)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Indivior Financial Performance
Revenues and expenses
Indivior Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Indivior stock?
Indivior (INDV) has a market cap of $3.1B as of September 05, 2025.
What is the P/E ratio for Indivior stock?
The price to earnings (P/E) ratio for Indivior (INDV) stock is 59.4 as of September 05, 2025.
Does Indivior stock pay dividends?
No, Indivior (INDV) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next Indivior dividend payment date?
Indivior (INDV) stock does not pay dividends to its shareholders.
What is the beta indicator for Indivior?
Indivior (INDV) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.